FIG. 3.

Administration of A20 increased progenitor cell and immature neuron proliferation 1 week post-TBI. Representative images showing BrdU- (A–D) and DCX-immunoreactive cells (E–H) in TBI vehicle- (left) and A20- (right) treated groups. Images in (C and D) and (G and H) are magnified regions of boxed areas in (A), (B), (E), and (F). (I and J) Quantification of BrdU- and DCX- positive cells. A20 administration significantly increased both BrdU- and DCX-positive cells, indicative of early stage neurogenesis (Student's t-test: BrdU: p=0.0163, t=2.665; DCX: p=0.0006, t=4.174; *p<0.05; ***p<0.001; scale bars, 200 μm); n=20. TBI, traumatic brain injury; BrdU, bromodeoxyuridine; DCX, doublecortin.